Close Menu

NEW YORK – Iovance Biotherapeutics and Cellectis announced Sunday that they were entering into a research collaboration and worldwide license agreement to develop personalized cancer therapies based on genetically edited tumor infiltrating lymphocytes (TILs). 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.